#USA #Santa Cruz #FDA Clearance #Emboline #Emboliner

Emboline Achieves Significant Milestone with FDA Clearance for the Emboliner® Embolic Protection System

Emboline, Inc., a trailblazer in medical technology focusing on next-gen embolic protection, proudly announces receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Emboliner® Embolic Protection System. This innovative device is designed specifically for use during transcatheter aortic valve replacement (TAVR) procedures, enhancing the safety and efficacy of these critically important heart interventions.

Comprehensive Embolic Protection

The Emboliner® system is engineered to deliver full cerebral and systemic embolic protection. Its primary function is to capture and eliminate embolic debris—potentially harmful particles that could disrupt blood flow and affect vital organs like the brain and kidneys. Unlike prior devices that merely cover selective cerebral vessels, the Emboliner features a unique circumferential dual-layer filter that secures both the brain and body circulation without obstructing the progress of the TAVR delivery system through its central working lumen.

This cutting-edge approach aims to alleviate a universal concern in TAVR procedures, which is the liberation of embolic debris that could compromise patient safety.

Clinical Validation

The recent FDA clearance stems from an extensive clinical evaluation process involving the PROTECT H2H IDE study. This multicenter, randomized study compared the Emboliner with the existing SENTINEL™ Cerebral Protection System during TAVR surgeries. Notable outcomes included surpassing primary safety and clinical performance objectives and capturing significantly more clinically relevant debris than previous devices. The Emboliner achieved the highest recorded technical success rate in TAVR embolic protection device studies, marking a pivotal moment in cardiac intervention technology.

These results have given both Emboline and the medical community renewed confidence in managing embolic risks associated with TAVR. Scott Russell, the President and CEO of Emboline, immodestly notes that this FDA clearance stands as a testament to the company’s long-standing commitment to addressing unmet medical needs in embolic protection.

Positive Reception from the Medical Community

Physicians, such as Dr. Tamim Nazif, co-director of the Structural Heart and Valve Center at Columbia University Irving Medical Center and a co-principal investigator in the recent study, have expressed that existing embolic protection methods have limited capabilities. Dr. Nazif highlighted that the Emboliner not only provides full brain and body protection but also integrates seamlessly into traditional TAVR procedures, which may bolster physician confidence when treating patients with elevated embolic risk.

The Road Ahead

Emboline is set to initiate a phased commercial launch in the United States starting later this year, which will include extensive training for physicians, gradual roll-out to selected centers, and ongoing collection of real-world clinical experience to further optimize the Emboliner’s usage in various medical settings.

Amir Belson, MD, the founder of Emboline, reflected on the groundbreaking nature of this achievement, emphasizing years of innovation, engineering, and clinical research that have culminated in making advanced protection available to patients and practitioners alike.

About Emboline

Founded with the vision to enhance safety in transcatheter cardiovascular procedures, Emboline, Inc. is based in Santa Cruz, California. The company is dedicated to advancing technologies that minimize embolic complications, ultimately transforming patient care in cardiology. The Emboliner® system exemplifies this mission and is expected to make waves in the medical community as it becomes widely accessible.

For further information, visit emboline.com.